Antiinflammatory Therapy with Canakinumab for Atherosclerotic DiseasePaul M. Ridker, Robert J. Glynn, Tom Thurén et al.|New England Journal of Medicine|2017Cited by 9.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trialPaul M. Ridker, Hakan Kültürsay, Alberto Lorenzatti et al.|The Lancet|2017Cited by 1.3k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trialPaul M. Ridker, Patrick Commerford, Jean MacFadyen et al.|The Lancet|2017Cited by 881
High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD)Isao Taguchi, Ryozo Nagai, Satoshi Iimuro et al.|Circulation|2018Cited by 242
JCS/CVIT/JCC 2023 Guideline Focused Update on Diagnosis and Treatment of Vasospastic Angina (Coronary Spastic Angina) and Coronary Microvascular DysfunctionSeiji Hokimoto, Hisao Ogawa, Koichi Kaikita et al.|Circulation Journal|2023Cited by 183